Samuel Singer

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Biochemical correlates of thiazolidinedione-induced adipocyte differentiation by high-resolution magic angle spinning NMR spectroscopy
    Jin Hong Chen
    Sarcoma Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Magn Reson Med 48:602-10. 2002
  2. ncbi request reprint Intensity modulated radiation therapy for primary soft tissue sarcoma of the extremity: preliminary results
    Kaled M Alektiar
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 68:458-64. 2007
  3. ncbi request reprint Long-term outcomes in extremity soft tissue sarcoma after a pathologically negative re-resection and without radiotherapy
    Oren Cahlon
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 112:2774-9. 2008
  4. ncbi request reprint Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors
    Samuel Singer
    Department of Pathology and Surgery, Brigham and Women s Hospital, Boston, MA, USA
    J Clin Oncol 20:3898-905. 2002
  5. pmc Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma
    Samuel Singer
    Sarcoma Disease Management Team, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10021, USA
    Ann Surg 238:358-70; discussion 370-1. 2003
  6. ncbi request reprint Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma
    Samuel Singer
    Sarcoma Biology Laboratory, Sarcoma Disease Management Program, Department of Surgery, Memorial Sloan Kettering Cancer Center and Genomics Core Facility, Sloan Kettering Institute, New York, NY 10021, USA
    Cancer Res 67:6626-36. 2007
  7. pmc Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis
    Jason S Gold
    Department of Surgery VA Boston Healthcare System Brigham and Women s Hospital West Roxbury, MA, USA
    Lancet Oncol 10:1045-52. 2009
  8. pmc Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors
    Narasimhan P Agaram
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Genes Chromosomes Cancer 47:853-9. 2008
  9. ncbi request reprint Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors
    Narasimhan P Agaram
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 13:170-81. 2007
  10. ncbi request reprint Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor
    Tianhua Guo
    Department of Pathology, Memorial Sloan Kettering Cancer Center, NY 10021, USA
    Clin Cancer Res 13:4874-81. 2007

Research Grants

  1. SOFT TISSUE SARCOMA PROGRAM PROJECT
    Samuel Singer; Fiscal Year: 2008

Collaborators

Detail Information

Publications97

  1. ncbi request reprint Biochemical correlates of thiazolidinedione-induced adipocyte differentiation by high-resolution magic angle spinning NMR spectroscopy
    Jin Hong Chen
    Sarcoma Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Magn Reson Med 48:602-10. 2002
    ..Thus, this ratio may be an NMR-detectable marker of troglitazone efficacy and response to differentiation therapy for liposarcoma...
  2. ncbi request reprint Intensity modulated radiation therapy for primary soft tissue sarcoma of the extremity: preliminary results
    Kaled M Alektiar
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 68:458-64. 2007
    ..To report preliminary results on using intensity modulated radiation therapy (IMRT) as an adjuvant treatment in primary soft tissue sarcoma (STS) of the extremity...
  3. ncbi request reprint Long-term outcomes in extremity soft tissue sarcoma after a pathologically negative re-resection and without radiotherapy
    Oren Cahlon
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 112:2774-9. 2008
    ....
  4. ncbi request reprint Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors
    Samuel Singer
    Department of Pathology and Surgery, Brigham and Women s Hospital, Boston, MA, USA
    J Clin Oncol 20:3898-905. 2002
    ..The aim of this study was to evaluate the prognostic relevance for KIT mutations in a series of GISTs in which the mutations were evaluated intensively by genomic and cDNA sequencing...
  5. pmc Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma
    Samuel Singer
    Sarcoma Disease Management Team, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10021, USA
    Ann Surg 238:358-70; discussion 370-1. 2003
    ..The aim of this study was to determine the pattern of recurrence and prognostic significance of histologic subtype in a large series of patients with primary retroperitoneal liposarcoma...
  6. ncbi request reprint Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma
    Samuel Singer
    Sarcoma Biology Laboratory, Sarcoma Disease Management Program, Department of Surgery, Memorial Sloan Kettering Cancer Center and Genomics Core Facility, Sloan Kettering Institute, New York, NY 10021, USA
    Cancer Res 67:6626-36. 2007
    ..These results support the development of a clinical trial with MDM2 antagonists for liposarcoma subtypes which overexpress MDM2 and show the promise of using this expression dataset for new drug discovery in liposarcoma...
  7. pmc Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis
    Jason S Gold
    Department of Surgery VA Boston Healthcare System Brigham and Women s Hospital West Roxbury, MA, USA
    Lancet Oncol 10:1045-52. 2009
    ..We aimed to develop a nomogram to predict RFS after surgery in the absence of adjuvant therapy to help guide patient selection for adjuvant imatinib therapy...
  8. pmc Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors
    Narasimhan P Agaram
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Genes Chromosomes Cancer 47:853-9. 2008
    ..A secondary V600E BRAF mutation could represent an alternative mechanism of imatinib resistance. Kinase inhibitors targeting BRAF may be effective therapeutic options in this molecular GIST subset...
  9. ncbi request reprint Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors
    Narasimhan P Agaram
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 13:170-81. 2007
    ..Our goal was to investigate the spectrum of pathologic response and molecular alterations in a group of GIST patients, clinically defined as having imatinib-stable/imatinib-responsive lesions, who underwent surgical resection...
  10. ncbi request reprint Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor
    Tianhua Guo
    Department of Pathology, Memorial Sloan Kettering Cancer Center, NY 10021, USA
    Clin Cancer Res 13:4874-81. 2007
    ....
  11. pmc Predictors of survival and recurrence in primary leiomyosarcoma
    Rebecca A Gladdy
    Sarcoma Disease Management Team, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 20:1851-7. 2013
    ..Thus, we sought to determine the factors that predict survival and recurrence in patients with primary leiomyosarcoma alone...
  12. doi request reprint Pediatric and adolescent synovial sarcoma: multivariate analysis of prognostic factors and survival outcomes
    Eric J Stanelle
    Pediatric Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 20:73-9. 2013
    ..Treatment of synovial sarcoma (SS) is challenging because of its unpredictable clinical behavior. We reviewed our institutional experience with pediatric SS to identify prognostic indicators and survival outcomes...
  13. doi request reprint Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity
    Kaled M Alektiar
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 26:3440-4. 2008
    ..The purpose of this study is to determine if such concern is warranted in soft-tissue sarcoma (STS) of the extremity...
  14. ncbi request reprint Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)
    Ronald P Dematteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 112:608-15. 2008
    ..Although the efficacy of tyrosine kinase inhibitors in metastatic GIST depends on tumor mutation status, there have been conflicting reports on the prognostic importance of KIT mutation in primary GIST...
  15. pmc Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance
    Tianhua Guo
    Departments of Pathology, Medicine, and Surgery, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, New York, NY 10021, USA
    Clin Cancer Res 15:6862-70. 2009
    ..The clinical benefit of sunitinib is genotype-dependent in regards to both primary and secondary mutations, with GIST patients harboring the KIT(AY502-3ins) exon 9 mutation being the most sensitive...
  16. pmc A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas
    Igor Matushansky
    Department of Pathology, Herbert Irving Comprehensive Cancer Center, Columbia University, 1130 St Nicholas Avenue, New York, NY 10032, USA
    Am J Pathol 172:1069-80. 2008
    ..Our results indicate that a degree of developmental maturity can be quantitatively assigned to solid tumors, supporting the notion that transformation of a solid tumor stem cell can occur at distinct stages of maturation...
  17. pmc Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors
    Jennifer LaFemina
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 20:66-72. 2013
    ..It is controversial whether patients with NF1-associated MPNST have worse outcomes. We investigated the prognostic significance of sporadic, NF1-associated, and RT-induced MPNST...
  18. pmc Patterns of deregulation of insulin growth factor signalling pathway in paediatric and adult gastrointestinal stromal tumours
    Antoine Italiano
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur J Cancer 48:3215-22. 2012
    ..Data regarding the patterns and the mechanisms of deregulation of the insulin growth factor (IGF) pathway in adult and paediatric gastrointestinal stromal tumours (GISTs) are limited...
  19. pmc The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification
    Antoine Italiano
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Genes Chromosomes Cancer 51:569-78. 2012
    ..Thus, MYC amplification may play a crucial role in the angiogenic phenotype of AS through upregulation of the miR-17-92 cluster, which subsequently downregulates THBS1, a potent endogenous inhibitor of angiogenesis...
  20. doi request reprint A postoperative nomogram for local recurrence risk in extremity soft tissue sarcomas after limb-sparing surgery without adjuvant radiation
    Oren Cahlon
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 255:343-7. 2012
    ..To develop a nomogram based on clinicopathologic factors to quantify the risk of local recurrence (LR) after limb-sparing surgery without adjuvant radiation (RT)...
  21. pmc Restoration of C/EBPα in dedifferentiated liposarcoma induces G2/M cell cycle arrest and apoptosis
    Yuhsin V Wu
    Sarcoma Biology Laboratory, Sarcoma Disease Management Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Genes Chromosomes Cancer 51:313-27. 2012
    ..These results demonstrate that loss of C/EBPα is an important factor in suppressing apoptosis and maintaining the dedifferentiated state in DDLS. Restoring C/EBPα may be a useful therapeutic approach for DDLS...
  22. ncbi request reprint Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells
    Elliot B Sambol
    Sarcoma Biology Laboratory, Sarcoma Disease Management Program, Department of Surgery and Laboratory of New Drug Development, Department Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Res 66:5858-66. 2006
    ..Our results indicate that targeting KIT expression and these antiapoptotic proteins with flavopiridol represents a novel means to disrupt GIST cell dependence on KIT signaling and collectively renders these cells sensitive to apoptosis...
  23. pmc Why do patients with low-grade soft tissue sarcoma die?
    Robert J Canter
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Surg Oncol 15:3550-60. 2008
    ..The patterns of failure and mechanisms of sarcoma-specific death are poorly characterized among the minority of patients with low-grade soft tissue sarcoma (STS) who succumb to disease...
  24. pmc Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas?
    Rebecca A Gladdy
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 1209, New York, NY 10065, USA
    J Clin Oncol 28:2064-9. 2010
    ..DSS in patients with primary RAS is significantly worse compared with sporadic STS independent of sarcoma histologic type...
  25. pmc Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells
    Grazia Ambrosini
    Laboratory of New Drug Development, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Mol Cancer Ther 7:890-6. 2008
    ..With growth inhibition at the low nanomolar range, sorafenib, by inhibiting the mitogen-activated protein kinase pathway, may prove to be a novel therapy for patients with MPNST...
  26. pmc Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma
    Mark A Dickson
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 31:2024-8. 2013
    ..In a phase I trial of PD0332991, several patients with WDLS or DDLS experienced prolonged stable disease. We performed an open-label phase II study to determine the safety and efficacy of PD0332991 in patients with advanced WDLS/DDLS...
  27. pmc The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial
    Jason J Luke
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Cancer Res 18:2638-47. 2012
    ..As such, we explored the potentiation of doxorubicin by flavopiridol in sarcoma, in vitro and in vivo, and conducted a phase I trial of flavopiridol with doxorubicin in patients with advanced sarcomas...
  28. pmc CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers
    Junwei Chen
    Department of Pathology, Memorial Sloan Kettering Cancer Center, NY, USA
    Genes Chromosomes Cancer 51:186-95. 2012
    ..Our results show that CD133 and CD44 are universally expressed in GIST, and may represent a lineage rather than a cancer stem cell marker...
  29. pmc Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions
    Tianhua Guo
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Genes Chromosomes Cancer 50:25-33. 2011
    ..Secondary genetic hits, such as FLT4 gene coamplification or KDR mutations, may play a role in tumor progression as well as potential therapeutic targeting...
  30. pmc Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk
    Kimberly Moore Dalal
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 244:381-91. 2006
    ..To determine the prognostic significance of histologic subtype in a large series of patients with primary liposarcoma (LS) and to construct a LS-specific postoperative nomogram for disease-specific survival (DSS)...
  31. pmc Novel ZC3H7B-BCOR, MEAF6-PHF1, and EPC1-PHF1 fusions in ossifying fibromyxoid tumors--molecular characterization shows genetic overlap with endometrial stromal sarcoma
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
    Genes Chromosomes Cancer 53:183-93. 2014
    ..As similar gene fusions were reported in endometrial stromal sarcomas, we screened for potential gene abnormalities in JAZF1 and EPC1 by FISH and found two additional cases with EPC1-PHF1 fusions...
  32. pmc Activity of Sorafenib against desmoid tumor/deep fibromatosis
    Mrinal M Gounder
    Departments of Medicine, Radiology, Pathology, and Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
    Clin Cancer Res 17:4082-90. 2011
    ..Responses of desmoid patients to sorafenib on an expanded access program led us to review our experience...
  33. pmc Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis
    Ryan M Gobble
    Department of Surgery, Sarcoma Disease Management Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Res 71:2697-705. 2011
    ....
  34. pmc Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas
    Barry S Taylor
    Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Cancer Discov 1:587-97. 2011
    ..These findings reveal an unanticipated role for epigenetic abnormalities in DLPS tumors and suggest demethylating agents as potential therapeutics...
  35. pmc Copy number losses define subgroups of dedifferentiated liposarcoma with poor prognosis and genomic instability
    Aimee M Crago
    Sarcoma Disease Management Program, Department of Surgery, Bioinformatics Core, Computational Biology Center, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 18:1334-40. 2012
    ..This study sought to identify copy number alterations (CNA) associated with dedifferentiation of WDLS, with DDLS morphology, and with patient outcomes...
  36. pmc Preclinical study of treatment response in HCT-116 cells and xenografts with (1) H-decoupled (31) P MRS
    Moses M Darpolor
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    NMR Biomed 24:1159-68. 2011
    ..The decrease in phosphocholine may be a potential indicator of early tumor response to the sequential treatment of irinotecan followed by flavopiridol in noninvasive and/or longitudinal studies...
  37. pmc Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor
    Ronald P Dematteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 245:347-52. 2007
    ..Nearly all tumors have an activating mutation in the KIT or, less often, PDGFRalpha, gene. Therapy with tyrosine kinase inhibitors benefits over 80% of patients with advanced GIST, but most patients eventually develop drug resistance...
  38. pmc ZIC1 overexpression is oncogenic in liposarcoma
    Elliott Brill
    Department of Surgery, Computational Biology Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer Res 70:6891-901. 2010
    ..Our results show that ZIC1 expression is essential for liposarcomagenesis and that targeting ZIC1 or its downstream targets might lead to novel therapy for liposarcoma...
  39. pmc Toward better soft tissue sarcoma staging: building on american joint committee on cancer staging systems versions 6 and 7
    Robert G Maki
    Tisch Cancer Institute, Departments of Medicine, Pediatrics and Orthopaedics, Mount Sinai School of Medicine, New York, NY, USA
    Ann Surg Oncol 20:3377-83. 2013
    ..Based on review of patient data in case conferences over time, we hypothesized that clinically relevant data are omitted in routine soft tissue sarcoma staging...
  40. pmc A prognostic nomogram for prediction of recurrence in desmoid fibromatosis
    Aimee M Crago
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Surg 258:347-53. 2013
    ..To construct a postoperative nomogram to estimate the risk of local recurrence for patients with desmoid tumors...
  41. pmc Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data
    Lu Wang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA
    Genes Chromosomes Cancer 51:127-39. 2012
    ..The novel HEY1-NCOA2 fusion appears to be the defining and diagnostic gene fusion in mesenchymal chondrosarcomas...
  42. ncbi request reprint Outcome of metastatic GIST in the era before tyrosine kinase inhibitors
    Jason S Gold
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Ann Surg Oncol 14:134-42. 2007
    ..Treatment of metastatic GIST with imatinib mesylate results in a 2-year survival of approximately 72%. The outcome of patients with metastatic GIST not treated with tyrosine kinase inhibitors is not well defined...
  43. pmc Advances in sarcoma genomics and new therapeutic targets
    Barry S Taylor
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Nat Rev Cancer 11:541-57. 2011
    ....
  44. pmc Predicting outcome by growth rate of locally recurrent retroperitoneal liposarcoma: the one centimeter per month rule
    James O Park
    Soft Tissue Sarcoma Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Surg 250:977-82. 2009
    ..To identify the prognostic variables that predict disease-specific survival and second local recurrence-free survival in patients with recurrent retroperitoneal liposarcoma so as to guide clinical management...
  45. pmc SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors
    Antoine Italiano
    Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    BMC Cancer 12:408. 2012
    ..A recent report identified four non-syndromic, KIT/PDGFRA WT GIST harboring compound heterozygous or homozygous mutations in SDHA encoding the main subunit of the SDH complex II...
  46. pmc Adult rhabdomyosarcoma survival improved with treatment on multimodality protocols
    Naamit Kurshan Gerber
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Int J Radiat Oncol Biol Phys 86:58-63. 2013
    ..Rhabdomyosarcoma (RMS) is a pediatric sarcoma rarely occurring in adults. For unknown reasons, adults with RMS have worse outcomes than do children...
  47. doi request reprint Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy
    Ryan C Fields
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 18:328-36. 2011
    ..We examine clinicopathologic factors associated with disease-free survival (DFS) in patients with primary and recurrent DFSP and evaluate responses to multimodality therapy...
  48. ncbi request reprint Prognostic factors for survival in patients with locally recurrent extremity soft tissue sarcomas
    Fritz C Eilber
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 12:228-36. 2005
    ..Factors prognostic for survival in patients with locally recurrent extremity soft tissue sarcomas (STS) are poorly defined, thus making it difficult to identify high-risk patients who may benefit from adjuvant therapy...
  49. pmc The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma
    Fritz C Eilber
    Departments of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg 240:686-95; discussion 695-7. 2004
    ..To determine if chemotherapy offers a survival benefit to patients with large, high-grade, primary extremity liposarcoma...
  50. ncbi request reprint Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity : a retrospective analysis
    Robert J Canter
    Division of Surgical Oncology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 110:2050-60. 2007
    ..To the authors' knowledge, few studies to date have examined the effect of chemotherapy in patients undergoing pulmonary resection for metastatic STS of the extremity...
  51. pmc KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer, New York, New York 10065, USA
    Cancer Res 69:7175-9. 2009
    ..These data provide a basis for the activity of vascular endothelial growth factor receptor-directed therapy in the treatment of primary and radiation-induced AS...
  52. pmc Small-Molecule targeting of translation initiation for cancer therapy
    Bertal H Aktas
    Department of Medicine, Brigham and Women s Hospital, Boston
    Oncotarget 4:1606-17. 2013
    ....
  53. pmc The enigma of myxofibrosarcoma of the extremity
    Robert W Mutter
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 118:518-27. 2012
    ..In this study, the authors compared rates and patterns of LR of high-grade (HG) myxofibrosarcoma with rates and patterns of HG leiomyosarcoma, which was chosen because of the similarity in incidence and general treatment approach...
  54. pmc A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients
    Robert J Canter
    Sarcoma Disease Management Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
    Clin Cancer Res 14:8191-7. 2008
    ..To identify prognostic factors related to outcome in 255 patients with synovial sarcoma and to construct a preoperative nomogram to predict the risk of disease-specific death...
  55. ncbi request reprint Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)
    Anette Duensing
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Oncogene 23:3999-4006. 2004
    ....
  56. pmc IGF2 over-expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting
    Mihai Hajdu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Pathol 221:300-7. 2010
    ..Our results confirm LOI in several tumours expressing high levels of IGF2, which may explain the observed paraneoplastic hypoglycaemia...
  57. pmc Functional copy-number alterations in cancer
    Barry S Taylor
    Computational Biology Center, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 3:e3179. 2008
    ..Taken together, we present a statistically robust methodology applicable to high-resolution genomic data to assess the extent and function of copy-number alterations in cancer...
  58. pmc Small RNA sequencing and functional characterization reveals MicroRNA-143 tumor suppressor activity in liposarcoma
    Stacy Ugras
    Department of Surgery, Sarcoma Biology Laboratory, Sarcoma Disease Management Program, The Rockefeller University, New York, New York, USA
    Cancer Res 71:5659-69. 2011
    ..Taken together, our findings suggest that miR-143 re-expression vectors or selective agents directed at miR-143 or its targets may have therapeutic value in dedifferentiated liposarcoma...
  59. doi request reprint Influence of compartmental involvement on the patterns of morbidity in soft tissue sarcoma of the thigh
    Andreas Rimner
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 115:149-57. 2009
    ..The authors sought to determine whether differences existed in patterns of outcome and morbidity between the 3 thigh compartments after limb-sparing surgery and postoperative radiation therapy (RT)...
  60. pmc A differentiation-based phylogeny of cancer subtypes
    Markus Riester
    Computational Biology Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    PLoS Comput Biol 6:e1000777. 2010
    ..Our algorithm represents the first phylogeny-based tool to analyze the differentiation status of human tumors...
  61. pmc Extraskeletal myxoid chondrosarcoma with non-EWSR1-NR4A3 variant fusions correlate with rhabdoid phenotype and high-grade morphology
    Narasimhan P Agaram
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065 Electronic address
    Hum Pathol 45:1084-91. 2014
    ..Furthermore, fluorescence in situ hybridization assay for NR4A3, along with EWSR1, may be an additional ancillary test to confirm diagnosis of EMCs. ..
  62. pmc PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis
    Dipak Panigrahy
    Surgical Research Laboratory, Children s Hospital, Department of Surgery, Harvard Medical School, Boston, Massachusetts, USA
    J Clin Invest 110:923-32. 2002
    ..These results suggest that PPARgamma ligands may be useful in treating angiogenic diseases such as cancer by inhibiting angiogenesis...
  63. pmc Blood neutrophil-to-lymphocyte ratio is prognostic in gastrointestinal stromal tumor
    Daniel R Perez
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 20:593-9. 2013
    ..The neutrophil-to-lymphocyte ratio (NLR) in blood is an easily assessable parameter of systemic inflammatory response. The aim of this study was to determine whether the NLR is prognostic in GIST...
  64. ncbi request reprint Soft tissue sarcoma diagnosed subsequent to lymphoma is associated with prior radiotherapy and decreased survival
    Steven C Katz
    Gastric and Mixed Tumor Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 117:4756-63. 2011
    ..Cancer survivors are at increased risk for second malignancies, and vigilance is thus required. The authors sought to determine whether there was an association among lymphoma, sarcoma, and the associated treatments for these diseases...
  65. pmc High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas
    Antoine Italiano
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Genes Chromosomes Cancer 51:207-18. 2012
    ..These results suggest the possibility of a newly defined subgroup of primitive round cell sarcomas characterized by CIC rearrangements, distinct from Ewing sarcoma family of tumors...
  66. ncbi request reprint Influence of site on the therapeutic ratio of adjuvant radiotherapy in soft-tissue sarcoma of the extremity
    Kaled M Alektiar
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 63:202-8. 2005
    ....
  67. ncbi request reprint Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation
    Cristina R Antonescu
    Department of Pathology, Sloan Kettering Institute, New York, New York, USA
    Clin Cancer Res 11:4182-90. 2005
    ..That acquired resistance to imatinib in GIST commonly occurs via secondary gene mutation in the KIT kinase domain has implications for strategies to delay or prevent imatinib resistance and to employ newer targeted therapies...
  68. ncbi request reprint Distant metastasis in retroperitoneal dedifferentiated liposarcoma is rare and rapidly fatal: a clinicopathological study with emphasis on the low-grade myxofibrosarcoma-like pattern as an early sign of dedifferentiation
    Hsuan Ying Huang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, NY 10021, USA
    Mod Pathol 18:976-84. 2005
    ..Irrespective of the grade dedifferentiated liposarcoma with myxofibrosarcoma-like features should be closely monitored. Once metastases occur, they tend to follow a rapidly fatal course...
  69. ncbi request reprint Isotropic susceptibility shift under MAS: the origin of the split water resonances in 1H MAS NMR spectra of cell suspensions
    Jin Hong Chen
    Sarcoma Disease Management Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Magn Reson Med 50:515-21. 2003
    ..The susceptibility difference was measured for three different cell types: 3T3 F442A preadipocyte cells, mouse embryonic stem cells, and human red blood cells...
  70. ncbi request reprint Liposarcoma subtypes: identification with computed tomography and ultrasound-guided percutaneous needle biopsy
    Paul Nikolaidis
    Department of Radiology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Eur Radiol 15:383-9. 2005
    ..Although these data cannot be extrapolated to primary diagnosis of liposarcoma, they are important for screening and subtyping of possible recurrence...
  71. ncbi request reprint Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
    George D Demetri
    Dana Farber Cancer Institute and Harvard Cancer Center, Boston, MA 02115, USA
    N Engl J Med 347:472-80. 2002
    ..Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against such tumors...
  72. ncbi request reprint Skeletal metastases in myxoid liposarcoma: an unusual pattern of distant spread
    Joseph H Schwab
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg Oncol 14:1507-14. 2007
    ..Anecdotal evidence, mainly supported by isolated case reports, suggests that a subset of these patients also develop bone metastasis, especially within the spine, which was previously under-appreciated...
  73. pmc Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
    Jordi Barretina
    Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA
    Nat Genet 42:715-21. 2010
    ..Our study yields a detailed map of molecular alterations across diverse sarcoma subtypes and suggests potential subtype-specific targets for therapy...
  74. pmc Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor)
    Veridiana Pires de Camargo
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065 6007, USA
    Cancer 116:2258-65. 2010
    ..In the current study, the authors examined the outcomes of patients with desmoid tumors who received systemic therapy at a single institution to provide a basis for the examination of newer agents...
  75. pmc Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy
    Alex D Drilon
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 113:3364-71. 2008
    ..To the authors' knowledge, there are limited data examining chemotherapy outcomes as a guide to therapeutic decisions for unresectable disease...
  76. ncbi request reprint Atypical lipomatous tumor/well-differentiated liposarcoma of the extremity and trunk wall: importance of histological subtype with treatment recommendations
    David A Kooby
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 11:78-84. 2004
    ..This study defines the behavior and classification of atypical lipomatous tumors (ALT) and well-differentiated liposarcomas (WDLS) of the extremity and trunk...
  77. ncbi request reprint Diagnosis and management of lipomatous tumors
    Kimberly Moore Dalal
    Department of Surgery, David Grant United States Air Force Medical Center, Travis Air Force Base, California 94535, USA
    J Surg Oncol 97:298-313. 2008
    ..A histologic-subtype specific nomogram provides accurate survival predictions. Prospective randomized clinical trials will continue to improve our care of patients with liposarcoma...
  78. pmc Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway
    Igor Matushansky
    Department of Medicine, Columbia University, New York, New York 10032, USA
    J Clin Invest 117:3248-57. 2007
    ..Our results provide mechanistic insights regarding the cell of origin of MFH, establish what we believe is a novel tumor suppressor role for Wnt signaling, and identify a potential therapeutic differentiation strategy for sarcomas...
  79. pmc Resolution of creatine and phosphocreatine 1H signals in isolated human skeletal muscle using HR-MAS 1H NMR
    Jin Hong Chen
    Sarcoma Disease Management Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Magn Reson Med 59:1221-4. 2008
    ..The resonance with the broader linewidth represents creatine that is significantly motion-restricted and suggests that a creatine pool in muscle tissue is highly compartmentalized...
  80. doi request reprint Local control comparison of adjuvant brachytherapy to intensity-modulated radiotherapy in primary high-grade sarcoma of the extremity
    Kaled M Alektiar
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 117:3229-34. 2011
    ..In recent years, intensity-modulated radiotherapy IMRT had been increasingly used. This study compared local control by IMRT versus by BRT in primary-extremity STS...
  81. pmc A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites
    Costantino Errani
    Department of Pathology, Sloan Kettering Cancer Center, New York, NY 10021, USA
    Genes Chromosomes Cancer 50:644-53. 2011
    ..Thus, FISH or RT-PCR analysis for the presence of WWTR1-CAMTA1 fusion may serve as a useful molecular diagnostic tool in challenging diagnoses...
  82. ncbi request reprint Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression
    Sam S Yoon
    Department of Surgery, Massachusetts General Hospital, Division of Surgical Oncology, Harvard Medical School, Boston, Massachusetts, USA
    J Surg Res 135:282-90. 2006
    ..The aim of this study was to develop profiles of angiogenesis-related gene and protein expression for various histologic subtypes of soft tissue sarcomas (STS) growing in different sites...
  83. doi request reprint Laparoscopic versus open gastric resections for primary gastrointestinal stromal tumors (GISTs): a size-matched comparison
    Giorgos C Karakousis
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 18:1599-605. 2011
    ..Tumor size however frequently plays a role in surgical approach with larger tumors tending toward laparotomy, raising concern that favorable outcomes reported for the laparoscopic approach may reflect this selection bias...
  84. pmc Fat-free MRI based on magnetization exchange
    Jin Hong Chen
    Sarcoma Disease Management Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Magn Reson Med 63:713-8. 2010
    ..Unlike most fat suppression techniques, this method is not compromised by the static or radiofrequency field heterogeneity and is equally efficient for all fat resonances independent of their chemical shift frequency...
  85. ncbi request reprint Multiple primary soft tissue sarcomas
    Stephen R Grobmyer
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 101:2633-5. 2004
    ..The synchronous or metachronous development of multiple primary soft tissue sarcomas (STS) of different histopathology has been reported only in isolated case reports...
  86. ncbi request reprint Validation of the postoperative nomogram for 12-year sarcoma-specific mortality
    Fritz C Eilber
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 101:2270-5. 2004
    ..Although this nomogram was found to be accurate by internal validation tests, it had not been validated in an external patient cohort, and thus its universal applicability remained unproven...
  87. ncbi request reprint Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma
    Robert Soiffer
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 21:3343-50. 2003
    ..We conducted a phase I clinical trial testing the biologic activity of vaccination with irradiated, autologous melanoma cells engineered to secrete GM-CSF by adenoviral-mediated gene transfer...
  88. ncbi request reprint Reconstruction after soft tissue sarcoma resection in the setting of brachytherapy: a 10-year experience
    Hung Yi Lee
    Plastic and Reconstructive Surgery Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Plast Surg 52:486-91; discussion 492. 2004
    ..Finally, removal of closed suction drainage tubes should be deferred until after the brachytherapy catheters are removed to minimize complications resulting from catheter dislodgement...
  89. ncbi request reprint Water suppression without signal loss in HR-MAS 1H NMR of cells and tissues
    Jin Hong Chen
    Sarcoma Disease Management Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Magn Reson 171:143-50. 2004
    ..This pulse sequence methodology enables efficient water suppression for intact cells and tissue samples and eliminates signal loss from cellular metabolites...
  90. doi request reprint A tribute to Murray F. Brennan, MD
    Samuel Singer
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
    J Surg Oncol 97:297. 2008
  91. ncbi request reprint Effectiveness of palliative procedures for intra-abdominal sarcomas
    Jen Jen Yeh
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg Oncol 12:1084-9. 2005
    ..Knowledge of the effectiveness of a procedure at achieving its palliative intent, as well as its attendant morbidity and mortality, is therefore paramount during this deliberation...
  92. ncbi request reprint Evaluation of a clinically applicable post-surgical classification system for primary retroperitoneal soft-tissue sarcoma
    Thijs van Dalen
    Dutch Soft Tissue Sarcoma Group, Vereniging van Integrale Kanker Centra, Utrecht, The Netherlands
    Ann Surg Oncol 11:483-90. 2004
    ..The objective of the present study was to develop a postsurgical classification system that would enable comparison of outcomes for patients with primary retroperitoneal soft-tissue sarcoma...
  93. pmc Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma
    Fritz C Eilber
    Division of Surgical Oncology, University of California Los Angeles, Los Angeles, CA, USA
    Ann Surg 246:105-13. 2007
    ..To determine if ifosfamide-based chemotherapy (IF) offers a survival benefit to adult patients with primary extremity synovial sarcoma...
  94. ncbi request reprint Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
    Michael C Heinrich
    R and D 19 3710 SW US Veterans Hospital Rd, Portland, OR 97207, USA
    J Clin Oncol 21:4342-9. 2003
    ..The relationship between mutations in these kinases and clinical response to imatinib was examined in a group of patients with advanced GIST...
  95. ncbi request reprint PDGFRA activating mutations in gastrointestinal stromal tumors
    Michael C Heinrich
    Department of Medicine, Department of Pathology, Oregon Health and Science University Cancer Institute and Portland VA Medical Center, Portland, OR 97201, USA
    Science 299:708-10. 2003
    ..Thus, KIT and PDGFRA mutations appear to be alternative and mutually exclusive oncogenic mechanisms in GISTs...
  96. ncbi request reprint Soft tissue sarcomas of adults: state of the translational science
    Ernest C Borden
    The Cleveland Clinic Foundation, Cleveland, Ohio, 44195, USA
    Clin Cancer Res 9:1941-56. 2003
    ..Finally, multicenter, coordinated trials, such as those that occurred with assessment of imatinib mesylate in metastatic gastrointestinal stromal tumors, will assure the most rapid reductions in morbidity and mortality...
  97. ncbi request reprint Coronary bypass surgery in women: a long-term comparative study of quality of life after bilateral internal mammary artery grafting in men and women
    Paul A Kurlansky
    Miami Heart Research Institute, Mount Sinai Medical Center, Miami Beach, Florida 33140, USA
    Ann Thorac Surg 74:1517-25. 2002
    ..The impact of arterial revascularization on long-term results, including quality of life (QOL) in women, compared with men, has not been clearly defined...

Research Grants1

  1. SOFT TISSUE SARCOMA PROGRAM PROJECT
    Samuel Singer; Fiscal Year: 2008
    ..This information will then be used to develop new targeted molecular therapeutics for soft tissue sarcoma. ..